Grateful. It’s a simple but powerful way to describe how we feel about you. As the world continues to navigate the ever-evolving COVID-19 pandemic, your care for Australians facing blood cancer remains unwavering.

Now more than ever, you’ve enabled the Leukaemia Foundation to be there for our blood cancer community in all the best ways possible. Your generosity has made sure all Australians living with blood cancer can access support driven by their individual needs.

Our face-to-face care is now enhanced with innovative new digital services and it’s been incredible to see people connecting and receiving support online across our country, be it from a farm, office, or hospital bed.

Equally important to support is hope. We recently celebrated the breakthrough listing of venetoclax on the Pharmaceutical Benefits Scheme for people living with acute myeloid leukaemia (AML). This development gives affordable access to a new treatment possibility for around 340 Australians with AML each year who might otherwise have run out of options. Thanks to our supporters, the Leukaemia Foundation contributed to the early development of venetoclax. And now, incredibly, we see that support transforming into real hope for families.

We’re so grateful to have you standing with us, putting patients first.

Chris Tanti
CEO
Leukaemia Foundation